nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—RET—autonomic nervous system—attention deficit hyperactivity disorder	0.0547	0.0858	CbGeAlD
Ponatinib—FGFR3—forebrain—attention deficit hyperactivity disorder	0.0185	0.029	CbGeAlD
Ponatinib—BCR—forebrain—attention deficit hyperactivity disorder	0.016	0.0251	CbGeAlD
Ponatinib—FGFR4—nervous system—attention deficit hyperactivity disorder	0.0147	0.0231	CbGeAlD
Ponatinib—FGFR4—central nervous system—attention deficit hyperactivity disorder	0.0142	0.0222	CbGeAlD
Ponatinib—FGFR4—cerebellum—attention deficit hyperactivity disorder	0.0138	0.0217	CbGeAlD
Ponatinib—FLT3—cardiovascular system—attention deficit hyperactivity disorder	0.0134	0.0211	CbGeAlD
Ponatinib—FGFR3—midbrain—attention deficit hyperactivity disorder	0.0122	0.0192	CbGeAlD
Ponatinib—FGFR2—forebrain—attention deficit hyperactivity disorder	0.0121	0.019	CbGeAlD
Ponatinib—FGFR4—brain—attention deficit hyperactivity disorder	0.0112	0.0177	CbGeAlD
Ponatinib—BCR—midbrain—attention deficit hyperactivity disorder	0.0106	0.0166	CbGeAlD
Ponatinib—PDGFRA—forebrain—attention deficit hyperactivity disorder	0.0105	0.0165	CbGeAlD
Ponatinib—SRC—forebrain—attention deficit hyperactivity disorder	0.0103	0.0162	CbGeAlD
Ponatinib—FGFR2—cardiovascular system—attention deficit hyperactivity disorder	0.0102	0.0161	CbGeAlD
Ponatinib—LYN—nervous system—attention deficit hyperactivity disorder	0.0101	0.0158	CbGeAlD
Ponatinib—FGFR3—nervous system—attention deficit hyperactivity disorder	0.01	0.0158	CbGeAlD
Ponatinib—TEK—cardiovascular system—attention deficit hyperactivity disorder	0.00981	0.0154	CbGeAlD
Ponatinib—LYN—central nervous system—attention deficit hyperactivity disorder	0.00972	0.0153	CbGeAlD
Ponatinib—FGFR3—central nervous system—attention deficit hyperactivity disorder	0.00967	0.0152	CbGeAlD
Ponatinib—KDR—forebrain—attention deficit hyperactivity disorder	0.00949	0.0149	CbGeAlD
Ponatinib—FGFR3—cerebellum—attention deficit hyperactivity disorder	0.00945	0.0148	CbGeAlD
Ponatinib—FGFR1—midbrain—attention deficit hyperactivity disorder	0.0094	0.0148	CbGeAlD
Ponatinib—PDGFRA—cardiovascular system—attention deficit hyperactivity disorder	0.00889	0.014	CbGeAlD
Ponatinib—SRC—cardiovascular system—attention deficit hyperactivity disorder	0.00872	0.0137	CbGeAlD
Ponatinib—BCR—nervous system—attention deficit hyperactivity disorder	0.00869	0.0136	CbGeAlD
Ponatinib—RET—midbrain—attention deficit hyperactivity disorder	0.00841	0.0132	CbGeAlD
Ponatinib—BCR—central nervous system—attention deficit hyperactivity disorder	0.00836	0.0131	CbGeAlD
Ponatinib—BCR—cerebellum—attention deficit hyperactivity disorder	0.00817	0.0128	CbGeAlD
Ponatinib—FLT3—cerebellum—attention deficit hyperactivity disorder	0.00812	0.0127	CbGeAlD
Ponatinib—KDR—cardiovascular system—attention deficit hyperactivity disorder	0.00802	0.0126	CbGeAlD
Ponatinib—LYN—brain—attention deficit hyperactivity disorder	0.00771	0.0121	CbGeAlD
Ponatinib—FGFR3—brain—attention deficit hyperactivity disorder	0.00767	0.012	CbGeAlD
Ponatinib—TEK—midbrain—attention deficit hyperactivity disorder	0.00766	0.012	CbGeAlD
Ponatinib—FGFR1—cerebellum—attention deficit hyperactivity disorder	0.00727	0.0114	CbGeAlD
Ponatinib—KIT—cardiovascular system—attention deficit hyperactivity disorder	0.00711	0.0112	CbGeAlD
Ponatinib—RET—nervous system—attention deficit hyperactivity disorder	0.00692	0.0109	CbGeAlD
Ponatinib—RET—central nervous system—attention deficit hyperactivity disorder	0.00666	0.0105	CbGeAlD
Ponatinib—BCR—brain—attention deficit hyperactivity disorder	0.00664	0.0104	CbGeAlD
Ponatinib—FGFR2—nervous system—attention deficit hyperactivity disorder	0.00657	0.0103	CbGeAlD
Ponatinib—RET—cerebellum—attention deficit hyperactivity disorder	0.00651	0.0102	CbGeAlD
Ponatinib—FGFR2—central nervous system—attention deficit hyperactivity disorder	0.00633	0.00993	CbGeAlD
Ponatinib—TEK—nervous system—attention deficit hyperactivity disorder	0.0063	0.00989	CbGeAlD
Ponatinib—KDR—midbrain—attention deficit hyperactivity disorder	0.00626	0.00983	CbGeAlD
Ponatinib—ABL1—cardiovascular system—attention deficit hyperactivity disorder	0.00619	0.00971	CbGeAlD
Ponatinib—FGFR2—cerebellum—attention deficit hyperactivity disorder	0.00618	0.00971	CbGeAlD
Ponatinib—TEK—central nervous system—attention deficit hyperactivity disorder	0.00607	0.00952	CbGeAlD
Ponatinib—TEK—cerebellum—attention deficit hyperactivity disorder	0.00593	0.00931	CbGeAlD
Ponatinib—FGFR1—brain—attention deficit hyperactivity disorder	0.00591	0.00927	CbGeAlD
Ponatinib—PDGFRA—nervous system—attention deficit hyperactivity disorder	0.00571	0.00896	CbGeAlD
Ponatinib—SRC—nervous system—attention deficit hyperactivity disorder	0.0056	0.00879	CbGeAlD
Ponatinib—KIT—midbrain—attention deficit hyperactivity disorder	0.00555	0.00871	CbGeAlD
Ponatinib—PDGFRA—central nervous system—attention deficit hyperactivity disorder	0.0055	0.00863	CbGeAlD
Ponatinib—SRC—central nervous system—attention deficit hyperactivity disorder	0.00539	0.00846	CbGeAlD
Ponatinib—PDGFRA—cerebellum—attention deficit hyperactivity disorder	0.00537	0.00843	CbGeAlD
Ponatinib—RET—brain—attention deficit hyperactivity disorder	0.00529	0.0083	CbGeAlD
Ponatinib—SRC—cerebellum—attention deficit hyperactivity disorder	0.00527	0.00827	CbGeAlD
Ponatinib—KDR—nervous system—attention deficit hyperactivity disorder	0.00515	0.00808	CbGeAlD
Ponatinib—FGFR2—brain—attention deficit hyperactivity disorder	0.00502	0.00789	CbGeAlD
Ponatinib—KDR—central nervous system—attention deficit hyperactivity disorder	0.00496	0.00778	CbGeAlD
Ponatinib—KDR—cerebellum—attention deficit hyperactivity disorder	0.00485	0.00761	CbGeAlD
Ponatinib—ABL1—midbrain—attention deficit hyperactivity disorder	0.00483	0.00759	CbGeAlD
Ponatinib—TEK—brain—attention deficit hyperactivity disorder	0.00482	0.00756	CbGeAlD
Ponatinib—KIT—nervous system—attention deficit hyperactivity disorder	0.00456	0.00716	CbGeAlD
Ponatinib—KIT—central nervous system—attention deficit hyperactivity disorder	0.00439	0.0069	CbGeAlD
Ponatinib—PDGFRA—brain—attention deficit hyperactivity disorder	0.00436	0.00685	CbGeAlD
Ponatinib—KIT—cerebellum—attention deficit hyperactivity disorder	0.00429	0.00674	CbGeAlD
Ponatinib—SRC—brain—attention deficit hyperactivity disorder	0.00428	0.00672	CbGeAlD
Ponatinib—ABL1—nervous system—attention deficit hyperactivity disorder	0.00397	0.00624	CbGeAlD
Ponatinib—KDR—brain—attention deficit hyperactivity disorder	0.00394	0.00618	CbGeAlD
Ponatinib—ABL1—central nervous system—attention deficit hyperactivity disorder	0.00382	0.006	CbGeAlD
Ponatinib—ABL1—cerebellum—attention deficit hyperactivity disorder	0.00374	0.00587	CbGeAlD
Ponatinib—KIT—brain—attention deficit hyperactivity disorder	0.00349	0.00548	CbGeAlD
Ponatinib—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00316	0.00497	CbGeAlD
Ponatinib—ABCG2—midbrain—attention deficit hyperactivity disorder	0.00305	0.00478	CbGeAlD
Ponatinib—ABL1—brain—attention deficit hyperactivity disorder	0.00304	0.00477	CbGeAlD
Ponatinib—ABCG2—cerebellum—attention deficit hyperactivity disorder	0.00236	0.0037	CbGeAlD
Ponatinib—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00228	0.00357	CbGeAlD
Ponatinib—CYP2C8—brain—attention deficit hyperactivity disorder	0.00197	0.00309	CbGeAlD
Ponatinib—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.00192	0.00302	CbGeAlD
Ponatinib—ABCG2—brain—attention deficit hyperactivity disorder	0.00191	0.00301	CbGeAlD
Ponatinib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00175	0.00274	CbGeAlD
Ponatinib—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.00172	0.0027	CbGeAlD
Ponatinib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00168	0.00264	CbGeAlD
Ponatinib—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00165	0.0026	CbGeAlD
Ponatinib—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.00162	0.00254	CbGeAlD
Ponatinib—ABCB1—midbrain—attention deficit hyperactivity disorder	0.0015	0.00236	CbGeAlD
Ponatinib—CYP2D6—brain—attention deficit hyperactivity disorder	0.00131	0.00206	CbGeAlD
Ponatinib—ABCB1—nervous system—attention deficit hyperactivity disorder	0.00124	0.00194	CbGeAlD
Ponatinib—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00119	0.00187	CbGeAlD
Ponatinib—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.00116	0.00182	CbGeAlD
Ponatinib—ABCB1—brain—attention deficit hyperactivity disorder	0.000944	0.00148	CbGeAlD
Ponatinib—SRC—Immune System—STUB1—attention deficit hyperactivity disorder	0.00037	0.00102	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000363	0.001	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00036	0.000992	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000357	0.000984	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000353	0.000972	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000347	0.000955	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000346	0.000953	CbGpPWpGaD
Ponatinib—SRC—Disease—STUB1—attention deficit hyperactivity disorder	0.000342	0.000942	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000341	0.000941	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00034	0.000936	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000339	0.000933	CbGpPWpGaD
Ponatinib—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000335	0.000924	CbGpPWpGaD
Ponatinib—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000333	0.000918	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000333	0.000917	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000332	0.000915	CbGpPWpGaD
Ponatinib—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000331	0.000912	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00033	0.000909	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000329	0.000905	CbGpPWpGaD
Ponatinib—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000329	0.000905	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000327	0.0009	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000326	0.000899	CbGpPWpGaD
Ponatinib—ABL1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000326	0.000897	CbGpPWpGaD
Ponatinib—FGFR4—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000324	0.000892	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000322	0.000888	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000321	0.000886	CbGpPWpGaD
Ponatinib—SRC—TGF-beta Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.000319	0.000879	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000319	0.000878	CbGpPWpGaD
Ponatinib—LCK—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000317	0.000874	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000316	0.00087	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000315	0.000868	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000314	0.000864	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00031	0.000853	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000309	0.000851	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000307	0.000845	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000298	0.000822	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000297	0.000819	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000284	0.000781	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000283	0.000779	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000281	0.000775	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000281	0.000775	CbGpPWpGaD
Ponatinib—SRC—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000281	0.000773	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000278	0.000765	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000277	0.000764	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000277	0.000762	CbGpPWpGaD
Ponatinib—FGFR2—Disease—SNAP25—attention deficit hyperactivity disorder	0.000272	0.000751	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000272	0.000751	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000271	0.000745	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000269	0.000742	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000269	0.00074	CbGpPWpGaD
Ponatinib—KIT—Disease—SNAP25—attention deficit hyperactivity disorder	0.000268	0.000737	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000264	0.000728	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000261	0.000719	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00026	0.000716	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000257	0.000709	CbGpPWpGaD
Ponatinib—FGFR1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000254	0.0007	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—SNAP25—attention deficit hyperactivity disorder	0.000253	0.000698	CbGpPWpGaD
Ponatinib—BCR—Disease—EP300—attention deficit hyperactivity disorder	0.000247	0.000681	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000243	0.00067	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000242	0.000666	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000239	0.00066	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000239	0.00066	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000237	0.000654	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000236	0.000651	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000235	0.000647	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000234	0.000645	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000232	0.00064	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000231	0.000635	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00023	0.000634	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00023	0.000634	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000228	0.000627	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000227	0.000626	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000225	0.000619	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000223	0.000615	CbGpPWpGaD
Ponatinib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000219	0.000604	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000219	0.000603	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000218	0.000601	CbGpPWpGaD
Ponatinib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000218	0.0006	CbGpPWpGaD
Ponatinib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000216	0.000596	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000214	0.00059	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000212	0.000583	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000206	0.000567	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000205	0.000566	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000202	0.000555	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000202	0.000555	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000198	0.000545	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000193	0.000532	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000193	0.000531	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000191	0.000527	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000191	0.000526	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000191	0.000526	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—EP300—attention deficit hyperactivity disorder	0.000189	0.000519	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000187	0.000516	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000186	0.000512	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000186	0.000512	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000185	0.000509	CbGpPWpGaD
Ponatinib—LCK—Disease—SNAP25—attention deficit hyperactivity disorder	0.000183	0.000505	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000183	0.000504	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000182	0.0005	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000181	0.0005	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000179	0.000494	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000178	0.000492	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000178	0.00049	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000177	0.000489	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000176	0.000485	CbGpPWpGaD
Ponatinib—FGFR4—Disease—EP300—attention deficit hyperactivity disorder	0.000174	0.00048	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000174	0.000479	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000173	0.000477	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000172	0.000475	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000172	0.000473	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—COMT—attention deficit hyperactivity disorder	0.00017	0.000469	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00017	0.000469	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00017	0.000468	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000169	0.000466	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000169	0.000466	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000169	0.000465	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000168	0.000464	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000167	0.000461	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000167	0.00046	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000167	0.00046	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000167	0.00046	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000165	0.000454	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000164	0.000452	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000164	0.000452	CbGpPWpGaD
Ponatinib—SRC—Disease—SNAP25—attention deficit hyperactivity disorder	0.000162	0.000447	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000162	0.000446	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000158	0.000435	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000156	0.000431	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000156	0.000429	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000155	0.000428	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000153	0.000423	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000153	0.000422	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000153	0.000421	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000153	0.000421	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000152	0.000419	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000152	0.000418	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—EP300—attention deficit hyperactivity disorder	0.00015	0.000413	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000149	0.000411	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000149	0.00041	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000149	0.000409	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000148	0.000408	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000147	0.000405	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000146	0.000401	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000141	0.00039	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00014	0.000387	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00014	0.000385	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—EP300—attention deficit hyperactivity disorder	0.000139	0.000384	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000138	0.00038	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000137	0.000378	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000137	0.000378	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000135	0.000372	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000134	0.00037	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000133	0.000367	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000133	0.000367	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000131	0.000361	CbGpPWpGaD
Ponatinib—FGFR3—Disease—EP300—attention deficit hyperactivity disorder	0.000129	0.000355	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000128	0.000353	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000124	0.000342	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000123	0.000339	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000122	0.000336	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.000336	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000122	0.000336	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000122	0.000336	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000121	0.000332	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000117	0.000323	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000115	0.000318	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000115	0.000318	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000115	0.000317	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000114	0.000313	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000113	0.000313	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000113	0.00031	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000112	0.000309	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000112	0.000308	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000111	0.000306	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000111	0.000305	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00011	0.000303	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000109	0.000301	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000109	0.0003	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000109	0.0003	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000108	0.000298	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000107	0.000294	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000106	0.000293	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000105	0.000291	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000101	0.000279	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.0001	0.000277	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.0001	0.000277	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.94e-05	0.000274	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	9.89e-05	0.000272	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—EP300—attention deficit hyperactivity disorder	9.8e-05	0.00027	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.6e-05	0.000264	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—EP300—attention deficit hyperactivity disorder	9.59e-05	0.000264	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	9.47e-05	0.000261	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.47e-05	0.000261	CbGpPWpGaD
Ponatinib—KIT—Immune System—EP300—attention deficit hyperactivity disorder	9.42e-05	0.00026	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	9.32e-05	0.000257	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.22e-05	0.000254	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.19e-05	0.000253	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.02e-05	0.000248	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	8.97e-05	0.000247	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—EP300—attention deficit hyperactivity disorder	8.94e-05	0.000246	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—EP300—attention deficit hyperactivity disorder	8.92e-05	0.000246	CbGpPWpGaD
Ponatinib—FGFR2—Disease—EP300—attention deficit hyperactivity disorder	8.86e-05	0.000244	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.78e-05	0.000242	CbGpPWpGaD
Ponatinib—KIT—Disease—EP300—attention deficit hyperactivity disorder	8.7e-05	0.00024	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.66e-05	0.000239	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EP300—attention deficit hyperactivity disorder	8.25e-05	0.000227	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EP300—attention deficit hyperactivity disorder	8.23e-05	0.000227	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	8.07e-05	0.000222	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.03e-05	0.000221	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	8.01e-05	0.000221	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.87e-05	0.000217	CbGpPWpGaD
Ponatinib—LYN—Immune System—EP300—attention deficit hyperactivity disorder	7.87e-05	0.000217	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.85e-05	0.000216	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EP300—attention deficit hyperactivity disorder	7.83e-05	0.000216	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.65e-05	0.000211	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.57e-05	0.000209	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—EP300—attention deficit hyperactivity disorder	7.31e-05	0.000201	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.21e-05	0.000199	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	6.99e-05	0.000193	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.97e-05	0.000192	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	6.94e-05	0.000191	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	6.73e-05	0.000185	CbGpPWpGaD
Ponatinib—LCK—Immune System—EP300—attention deficit hyperactivity disorder	6.45e-05	0.000178	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.2e-05	0.000171	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	6.19e-05	0.000171	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.19e-05	0.000171	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	6.09e-05	0.000168	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.09e-05	0.000168	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	6.09e-05	0.000168	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	6.05e-05	0.000167	CbGpPWpGaD
Ponatinib—LCK—Disease—EP300—attention deficit hyperactivity disorder	5.95e-05	0.000164	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.78e-05	0.000159	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.77e-05	0.000159	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	5.74e-05	0.000158	CbGpPWpGaD
Ponatinib—SRC—Immune System—EP300—attention deficit hyperactivity disorder	5.71e-05	0.000157	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	5.7e-05	0.000157	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.66e-05	0.000156	CbGpPWpGaD
Ponatinib—SRC—Disease—EP300—attention deficit hyperactivity disorder	5.27e-05	0.000145	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.09e-05	0.00014	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.95e-05	0.000136	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—EP300—attention deficit hyperactivity disorder	4.83e-05	0.000133	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.71e-05	0.00013	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.17e-05	0.000115	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	3.75e-05	0.000103	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	3.72e-05	0.000103	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.69e-05	0.000102	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	3.46e-05	9.53e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	3e-05	8.26e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	2.61e-05	7.19e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	2.46e-05	6.78e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	1.61e-05	4.43e-05	CbGpPWpGaD
